Turnaround progress masks tissue-thin Q1 margins at 0.2%

NPM 0.2%, OPM 2.7%—margins are tissue-thin. EBITDA +6% but PAT essentially flat after working capital costs.

Sugar drives segment performance well (₹14 Cr PBIT up 82%), but total firm PAT ₹3.6 Cr indicates water/spirits losses offset gains.

Supported by lower maize costs, better DDGS realisations, cost optimisation—segment performing well.

Call held July 30; now says 4-6 weeks from then → mid-Sep to early-Oct 2026. ~4-week delay vs prior guidance.

Reduction of ₹365 Cr confirmed; cost of funds down 70 bps to 6.8%. Debt management solid.

Promised end-August 2026; now 4-6 weeks from July 30 call = mid-Sep to Oct. ~4-week slip on prior commitment.

Gross recovery +26 bps to 11.1% vs prior season 10.85% (approx). Cane development initiatives working; crop health described as 'excellent'.

PBIT +32% to ₹31 Cr vs Q1 FY26 despite 19% volume decline. Cost optimisation programme delivering; DDGS realisations up; maize prices stabilising.

Revenue -21% to ₹43 Cr; Prayagraj/Vadodara EPC execution slower than expected. Order book healthy but cash conversion weak.

Intensive cane development initiatives, pest monitoring, improved rainfall distribution, crop health excellent. Expect better outcome next season; still 6 weeks critical before season start.

Generic: 'Bottlenecks are part of business. We expect to achieve operating plans for full year.' No specifics on delays or remediation.

Flattish performance expected; modest dilution vs last year. National balance sheet sufficient. Monsoon fears mitigated by recent 30-40 day recovery.

Next year ~1,300 Cr L procurement (optimistic). Many standalone distilleries at 20-50% utilisation; interest moratorium expires, viability questioned. Multi-feed players (like Triveni) will outperform. 70% not sacrosanct—mix varies by company.

Board deliberating actively. Cannot disclose specific areas yet. Triveni historically an incubator (turbine, defence, PTBL spun off). Will revert when board concludes.

95-96% is country liquor (profitable); balance is branded spirits (not yet profitable). Will expand in UP/Delhi judiciously. No major capex until market traction proven. Top-5 in UP in 4 years already.

Uncertain. Last year ₹30/quintals increase was record high. Election year sensitive but large increase last year. Some arrears still exist. Will likely be 'seriously moderated' if any. UP govt decision.

It represents PAT only (not PBIT). Q1 FY27 was strong, better than prior year. Historical comparisons need PBIT apples-to-apples. Full disclosure will come post-listing.

Cannot disclose; TPTL is separate company now, results to follow post-listing. West Asia crisis impacted Q4 more than Q1; normalcy returning; oil >$100 = good (more CapEx). Full commentary deferred.

Pricing ₹4,600/quintal current vs ₹4,525 sulphitation. Government stock control limits Aug-Nov 2026 supportive. No numeric FY27 target.

Assumes 'normalcy of business and environment.' Supreme Court ethanol allocation ruling pending. Multi-feed capacity needed to compete. No firm Triveni volume target.

Depends on cane yields, recovery, cost inflation. No numeric OPM/NPM target given. Current 2.7% OPM tissue-thin.

Maize prices expected modest; DDGS upside from higher usage. No numeric target. Vulnerable to commodity swings.

Some capex already incurred. Shamli expected significant rebound in 2026-27. No multi-year capex or ₹ amount disclosed.

Q1 delivered 0.2% NPM. A 5% adverse move in sugar prices or 10% maize spike could flip to loss. No hedging disclosed.

Revenue down 21% YoY. Order book ₹1,472 Cr but cash conversion poor. MD provided generic response on bottlenecks.

Alcohol sales volume down 19% YoY. Ethanol allocation to OMCs frozen pending court ruling. MD defended ethanol at length vs criticism.

4-week slip already vs guidance. Further delays erode investor confidence and refinance optionality.

Shamli factory had operational issues, unseasonal farming practices depressed crop quality. MD expects 'massive rebound' in 2026-27 but unproven.